INT20389

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.79
First Reported 1983
Last Reported 2009
Negated 0
Speculated 1
Reported most in Abstract
Documents 19
Total Number 20
Disease Relevance 4.58
Pain Relevance 6.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (LYZ) hydrolase activity, acting on glycosyl bonds (LYZ) extracellular region (LYZ)
Anatomy Link Frequency
neutrophils 8
monocyte 2
blood 1
plasma 1
tears 1
LYZ (Homo sapiens)
Pain Link Frequency Relevance Heat
anesthesia 12 99.92 Very High Very High Very High
lidocaine 12 98.82 Very High Very High Very High
Serotonin 1 98.44 Very High Very High Very High
adenocard 16 97.90 Very High Very High Very High
Inflammation 127 97.06 Very High Very High Very High
cINOD 12 96.96 Very High Very High Very High
Enkephalin 9 95.08 Very High Very High Very High
local anesthetic 1 94.20 High High
tolerance 2 91.44 High High
Paracetamol 3 91.32 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 139 97.06 Very High Very High Very High
Bacterial Respiratory Disease 1 95.44 Very High Very High Very High
Hemorrhage 1 93.76 High High
Apoptosis 3 91.40 High High
Infection 6 89.32 High High
Leukemia 9 88.80 High High
Granuloma 1 88.24 High High
Cancer 7 87.68 High High
Pneumocystis Pneumonia 2 86.60 High High
Coronary Artery Disease 2 84.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Some remarkable effects of thiopeptide and derived linkages on lysozyme release from neutrophils by esters of the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (f-Met-Leu-Phe-OR).
Localization (release) of lysozyme in neutrophils
1) Confidence 0.79 Published 1989 Journal Int. J. Immunopharmacol. Section Title Doc Link 2807625 Disease Relevance 0 Pain Relevance 0.08
A variety of recently synthesized analogues of the chemotactic agent f-Met-Leu-Phe-OR modified in the backbone were tested for their ability to induce the release of lysozyme from human neutrophils.
Localization (release) of lysozyme in neutrophils
2) Confidence 0.79 Published 1989 Journal Int. J. Immunopharmacol. Section Abstract Doc Link 2807625 Disease Relevance 0 Pain Relevance 0.09
Effect of topical anesthesia on secretion of lysozyme and lysosomal enzymes in human tears.
Localization (secretion) of lysozyme in tears associated with anesthesia
3) Confidence 0.65 Published 1989 Journal Jpn. J. Ophthalmol. Section Title Doc Link 2796016 Disease Relevance 0 Pain Relevance 0.48
Results of a Schirmer's test with 0.4% oxybuprocaine showed that topical anesthesia reduced the mean test value by 47% and the secretion of protein, lysozyme, acid phosphatase, and N-acetyl-beta-D-glucosaminidase by 30%, 45%, 31%, and 33%, respectively.
Localization (secretion) of lysozyme associated with anesthesia
4) Confidence 0.65 Published 1989 Journal Jpn. J. Ophthalmol. Section Abstract Doc Link 2796016 Disease Relevance 0 Pain Relevance 0.34
Leukotriene B4 (LTB4) induced human neutrophils (Neu) aggregation with thromboxane B2/prostaglandin E2 formation and lysozyme release, enhanced platelet aggregation and/or serotonin release caused by threshold concentrations of calcimycin or ADP, and increased Neu adherence to human umbilical vein endothelial cells.
Localization (release) of lysozyme in neutrophils associated with serotonin
5) Confidence 0.63 Published 1993 Journal Zhongguo Yao Li Xue Bao Section Abstract Doc Link 8394638 Disease Relevance 0 Pain Relevance 0.12
The COx inhibitor ibuprofen inhibited FMLP-induced aggregation and lysozyme secretion, leaving O2- generation unaffected.
Localization (secretion) of lysozyme
6) Confidence 0.46 Published 1984 Journal Inflammation Section Abstract Doc Link 6090311 Disease Relevance 0.16 Pain Relevance 0.07
Gpp(NH)p, a GTPase insensitive analog of GTP, also inhibited the binding of FMLP but, paradoxically, enhanced superoxide anion generation and lysozyme release.
Localization (release) of lysozyme
7) Confidence 0.46 Published 1990 Journal Inflammation Section Abstract Doc Link 2138998 Disease Relevance 0.15 Pain Relevance 0.81
We found that lidocaine added to human neutrophils in vitro markedly impaired the release of superoxide anion (O2-) and the granule enzymes lysozyme and myeloperoxidase after stimulation by phorbol myristate acetate or opsonized zymosan.
Localization (release) of lysozyme in neutrophils associated with lidocaine
8) Confidence 0.45 Published 1985 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2997433 Disease Relevance 0.26 Pain Relevance 0.82
The production of O2- from neutrophils was not affected by N/OFQ while the release of lysozyme was increased in a concentration dependent manner (pEC50 11.00) although the maximal effects evoked by N/OFQ were about half of those of fMLP.
Localization (release) of lysozyme in neutrophils
9) Confidence 0.41 Published 2005 Journal Peptides Section Abstract Doc Link 15922491 Disease Relevance 0 Pain Relevance 0.34
We have studied the role of arachidonic acid (AA) metabolism in the release of lysosomal enzymes (beta-glucuronidase and lysozyme) from human polymorphonuclear leukocytes (PMNs). 5,8,11,14-Eicosatetraenoic acid (ETYA), which inhibits both the cyclo-oxygenase and the lipoxygenase pathways of AA metabolism, was found to cause a dose-dependent inhibition of lysosomal enzyme release from human PMNs induced by immunological (i.e., serum-treated zymosan: Zx) and nonimmunological stimuli (i.e., formyl methionine-containing peptide and the Ca2+ ionophore A23187).
Localization (release) of lysozyme in PMNs
10) Confidence 0.41 Published 1983 Journal J Clin Lab Immunol Section Abstract Doc Link 6644791 Disease Relevance 0.06 Pain Relevance 0.09
In the present study we investigated the ability of N/OFQ, in comparison with the proinflammatory peptide formyl-Met-Leu-Phe (fMLP), to stimulate human neutrophil and monocyte chemotaxis and the release of lysozyme and superoxide anion (O2-) production from neutrophils. fMLP stimulated all the leukocyte functions examined.
Localization (release) of lysozyme in monocyte
11) Confidence 0.32 Published 2005 Journal Peptides Section Abstract Doc Link 15922491 Disease Relevance 0 Pain Relevance 0.28
MetEKamide was able to induce degranulation when present at 10(-3) and 10(-4) mmol/L as determined by release of beta-glucuronidase and lysozyme.
Spec (determined) Localization (release) of lysozyme
12) Confidence 0.28 Published 1987 Journal J Burn Care Rehabil Section Abstract Doc Link 3436973 Disease Relevance 0.08 Pain Relevance 0.67
Cytochrome c reduction and the release of lysozyme, beta-glucuronidase, myeloperoxidase and gelatinase were measured.
Localization (release) of lysozyme
13) Confidence 0.25 Published 1987 Journal Biochem. Pharmacol. Section Abstract Doc Link 3038127 Disease Relevance 0.17 Pain Relevance 0.12
Prostaglandin E2, acting through its own set of receptors, is also a potent inhibitor of neutrophil inflammatory functions and can, similarly to adenosine, modulate pivotal neutrophil effector functions such as chemotaxis, aggregation, superoxide production, lysozyme release and leukotriene B4 production by raising intracellular cyclic AMP concentration above basal levels [22], [26]–[33].
Localization (release) of lysozyme in neutrophil associated with adenocard and inflammation
14) Confidence 0.21 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2654409 Disease Relevance 0.60 Pain Relevance 0.46
The scope of investigations included in vitro tests such as the determination of protein binding, the inhibition of complement, lysozyme, urokinase, platelet aggregation, the release of histamine, the influence on thromboplastin time.
Localization (release) of lysozyme in platelet
15) Confidence 0.16 Published 1994 Journal Arzneimittelforschung Section Abstract Doc Link 7529504 Disease Relevance 0.09 Pain Relevance 0.05
CS and its fractions inhibit the directional chemotaxis induced by zymosan-activated serum, are able to decrease the phagocytosis and the release of lysozyme induced by zymosan and to protect the plasma membrane from oxygen reactive species.
Localization (release) of lysozyme in plasma
16) Confidence 0.11 Published 1998 Journal Osteoarthr. Cartil. Section Abstract Doc Link 9743814 Disease Relevance 0.45 Pain Relevance 0.15
In the present study we investigated the ability of N/OFQ, in comparison with the proinflammatory peptide formyl-Met-Leu-Phe (fMLP), to stimulate human neutrophil and monocyte chemotaxis and the release of lysozyme and superoxide anion (O2-) production from neutrophils. fMLP stimulated all the leukocyte functions examined.
Localization (release) of lysozyme in neutrophil
17) Confidence 0.11 Published 2005 Journal Peptides Section Abstract Doc Link 15922491 Disease Relevance 0 Pain Relevance 0.28
Lysozyme is also released by three types of granules [52].
Localization (released) of Lysozyme
18) Confidence 0.08 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2639705 Disease Relevance 0.50 Pain Relevance 0.21
-actinin fragments significantly increase lysozyme secretion and tartate-resistant acid phosphatase staining in peripheral blood monocytes.
Localization (secretion) of lysozyme in blood
19) Confidence 0.02 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC333421 Disease Relevance 0.78 Pain Relevance 0.27
We have previously reported that mactinin promotes monocyte maturation, as measured by lysozyme secretion and tartrate-resistant acid phosphatase staining [7].
Localization (secretion) of lysozyme in monocyte
20) Confidence 0.02 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC333421 Disease Relevance 1.28 Pain Relevance 0.52

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox